PROGRAM CHAIR & FACULTY PRESENTER
Omid Hamid, MD
Chief of Research/Immuno-Oncology
The Angeles Clinic and Research Institute
Co-Director, Cutaneous Malignancy Program
Cedars-Sinai Cancer Institute
Los Angeles, CA
PROGRAM OVERVIEW
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about biomarkers that guide treatment selection, novel immunotherapy treatment strategies, and the critical role of multidisciplinary management to individualize care in melanoma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of medical oncologists, hematologic-oncologists, academic, community and research oncologists, and collaborative multidisciplinary care professionals who manage patients with Melanoma.
EDUCATIONAL OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess updates in tumor assessment, including targetable mutations and considerations for eligibility with immuno-therapeutic options for cancer management.
- Explain the latest developments in therapeutics, including developments in novel targeted and immuno-therapeutic mechanisms in melanoma.
- Summarize best practices for monitoring and management of potential unique adverse events associated with novel therapeutics.
- Evaluate best practices for integrating patient advocacy and optimal communication in oncology care.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosure |
| Omid Hamid, MD | Dr. Hamid reports he is a consultant for Alkermes, Amgen, Bactonix, Beigene, BioAtla, BMS, Eisai Biotech, Roche Genentech, Georgiamune, GigaGen, Grit Bio, GSK, ldera, Immunocore, lncyte, lnstil bio, I0 Biotech, lovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, and Zelluna. He is also on the speakers bureaus for BMS, Immunocore, Novartis, Pfizer, and Regeneron. Dr. Hamid also reports stock in Bactonix. |
All relevant financial relationships have been mitigated.
CME CONTENT REVIEW
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE CONTENT REVIEW
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
STAFF PLANNERS AND MANAGERS
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Ingrid Peterson, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 15, 2023
EXPIRATION DATE: June 15, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
